Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Karyopharm Therapeutics Inc. (KPTI) reports that Affinity Asset Advisors, LLC and its managing member, Michael Cho, beneficially owned 1,573,517 shares issuable upon exercise of warrants as of September 30, 2026. The shares are directly held by Affinity Healthcare Fund, LP; the Adviser exercises voting and investment power over them, and Cho may be deemed a beneficial owner through his role as the Adviser’s managing member. The reported stake was 6.5%, calculated using a 24,254,977-share denominator as of August 6, 2026: 22,681,460 common shares outstanding plus 1,573,517 shares issuable upon warrant exercise. The warrants are subject to a 9.99% beneficial ownership limitation.
Key Figures
Beneficially owned warrant shares:1,573,517 sharesReported ownership percentage:6.5%Ownership-percentage denominator:24,254,977 shares+2 more
5 metrics
Beneficially owned warrant shares1,573,517 sharesShares issuable upon exercise of warrants, as of September 30, 2026
Reported ownership percentage6.5%As of September 30, 2026
Ownership-percentage denominator24,254,977 sharesAs of August 6, 2026; consists of 22,681,460 common shares outstanding plus 1,573,517 shares issuable upon warrant exercise
Common shares outstanding22,681,460 sharesAs of August 6, 2026
Beneficial ownership limitation9.99%Limit applicable to the warrants after giving effect to issuance of warrant shares
"subject to a beneficial ownership limitation of 9.99%"
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
Warrantsfinancial
"shares issuable upon the exercise of warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
investment management agreementfinancial
"pursuant to an investment management agreement"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many KPTI shares did Affinity report beneficial ownership of?
Affinity Asset Advisors, LLC and Michael Cho reported beneficial ownership of 1,573,517 shares issuable upon exercise of warrants as of September 30, 2026. The shares are directly held by Affinity Healthcare Fund, LP.
What is the beneficial ownership limit on the KPTI warrants?
The warrants are subject to a 9.99% beneficial ownership limitation, measured against Karyopharm common shares outstanding immediately after giving effect to the warrant-share issuance.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
Karyopharm Therapeutics Inc.
(Name of Issuer)
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
48576U205
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
48576U205
1
Names of Reporting Persons
Affinity Asset Advisors, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,573,517.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,573,517.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,573,517.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
OO, IA
SCHEDULE 13G
CUSIP Number(s):
48576U205
1
Names of Reporting Persons
Michael Cho
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
1,573,517.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
1,573,517.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,573,517.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.5 %
12
Type of Reporting Person (See Instructions)
IN, HC
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Karyopharm Therapeutics Inc.
(b)
Address of issuer's principal executive offices:
85 Wells Avenue, 2nd Floor, Newton, MA 02459
Item 2.
(a)
Name of person filing:
Affinity Asset Advisors, LLC
Michael Cho
(b)
Address or principal business office or, if none, residence:
450 Park Avenue
Suite 1403
New York, NY 10022
(c)
Citizenship:
Affinity Asset Advisors, LLC is a Delaware limited liability company, and Michael Cho is an individual and is a citizen of the United States.
(d)
Title of class of securities:
Common Stock, $0.0001 par value per share
(e)
CUSIP No.:
48576U205
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The securities reported herein are directly held by Affinity Healthcare Fund, LP (the "Fund"). Affinity Asset Advisors, LLC (the "Adviser") is the investment manager of the Fund and exercises voting and investment power over the securities held directly by the Fund reported herein pursuant to an investment management agreement between the Adviser, the Fund, and the general partner of the Fund. The Adviser may be deemed to beneficially own the securities reported herein held by the Fund by virtue of its position as investment manager of the Fund. Michael Cho, the managing member of the Adviser, may be deemed a beneficial owner of the securities reported herein held by the Fund.
As of September 30, 2026, the Adviser and Mr. Cho (collectively, the "Reporting Persons") beneficially own 1,573,517 shares of Common Stock, $0.0001 par value per share ("Common Stock"), of Karyopharm Therapeutics Inc. (the "Issuer") issuable upon the exercise of warrants (the "Warrants"). The Warrants are all subject to a beneficial ownership limitation of 9.99% of the number of shares of Common Stock of the Issuer outstanding immediately after giving effect to the issuance of the shares issuable upon exercise of the Warrants (the "Beneficial Ownership Limitation").
(b)
Percent of class:
As of September 30, 2026, the Reporting Persons beneficially own 6.5% of the Common Stock outstanding.
The percentages disclosed above are based on 24,254,977 shares of Common Stock of the Issuer outstanding as of August 6, 2026, consisting of (a) the 22,681,460 shares of Common Stock of the Issuer outstanding as of August 6, 2026, as set forth in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on August 13, 2026, and (b) 1,573,517 shares of Common Stock issuable upon the exercise of Warrants held by the Fund.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
As of September 30, 2026, the Reporting Persons have sole power to vote or to direct the vote of 1,573,517 shares of Common Stock issuable upon the exercise of warrants after giving effect to the Beneficial Ownership Limitation.
(ii) Shared power to vote or to direct the vote:
As of September 30, 2026, the Reporting Persons have shared power to vote or to direct the vote of 0 shares of Common Stock.
(iii) Sole power to dispose or to direct the disposition of:
As of September 30, 2026, the Reporting Persons have sole power to dispose or to direct the disposition of 1,573,517 shares of Common Stock issuable upon the exercise of warrants after giving effect to the Beneficial Ownership Limitation.
(iv) Shared power to dispose or to direct the disposition of:
As of September 30, 2026, the Reporting Persons have shared power to dispose or to direct the disposition of 0 shares of Common Stock.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Affinity Asset Advisors, LLC
Signature:
/s/ Andrew Weinstein
Name/Title:
Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer